Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lasmiditan Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

NCT03286218
View directory record Official record
Conditions
Recreational Drug Use, Prescription Drug Abuse (Not Dependent)
Interventions
Lasmiditan, Alprazolam, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

NCT03040479
View directory record Official record
Conditions
Migraine
Interventions
lasmiditan 200 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants

NCT03459612
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Placebo, Diphenhydramine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate

NCT03308669
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Placebo, Topiramate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Multiple Doses of Lasmiditan in Healthy Participants

NCT03252015
View directory record Official record
Conditions
Healthy
Interventions
Probe Drug Cocktail, Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

NCT03310411
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Sumatriptan, Placebo for Lasmiditan, Placebo for Sumatriptan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan in Participants With Migraine

NCT03247790
View directory record Official record
Conditions
Migraine Disorders
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
San Diego, California • Hialeah, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

NCT03670810
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

NCT03076970
View directory record Official record
Conditions
Migraine
Interventions
lasmiditan 200 mg, Sumatriptan, matching placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan in Healthy Elderly Participants

NCT03406260
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Daytona Beach, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants

NCT04881747
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 18, 2026, 7:05 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396236
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
77
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration

NCT03040362
View directory record Official record
Conditions
Healthy
Interventions
[14C]-lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 18, 2026, 7:05 AM EDT
Terminated Phase 3 Interventional Results available

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396574
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
71
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan in Healthy Participants

NCT03182920
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Results available

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

NCT03988088
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Newport Beach, California • Stamford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan and Propranolol in Healthy Participants

NCT03270644
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Propranolol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

NCT02565186
View directory record Official record
Conditions
Migraine Disorders
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
182
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:

NCT02439320
View directory record Official record
Conditions
Acute Migraine
Interventions
Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo (matches lasmiditan doses)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
92
States / cities
Birmingham, Alabama • Chandler, Arizona • Fountain Hills, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

NCT02605174
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 18, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan in Healthy Japanese and Caucasian Participants

NCT03579940
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 18, 2026, 7:05 AM EDT